Ajanta Pharma gains on USFDA nod for Almotriptan Malate tablets

The tablets are used for the treatment of acute migraine pain relief

Shares of Ajanta Pharma were up nearly 3% at Rs 1,435 after the company said it has received final approval of Almotriptan Malate tablets in dosages of 6.25mg and 12.5mg.

The tablets are the generic version of Axert which are dispensed for the treatment of acute migraine pain relief. Ajanta Pharma USA Inc., a wholly-owned subsidiary of Ajanta Pharma Ltd, is scheduled to launch Almotriptan tables in US shortly, the company said in a release.

Till date, USFDA has granted Ajanta Pharma eight ANDA final approvals and two tentative approvals, the release added.

The stock opened at Rs 1,421 and touched a high of Rs 1,449. At 10am, over 74,000 shares were traded on both the stock exchanges.